#Tar200

Breakthrough medical technology offers new hope for thousands of Thai patients who might otherwise lose their bladders to cancer, with promising results from international trials suggesting a paradigm shift in urological care.

In a development that could transform bladder cancer treatment across Thailand, researchers have unveiled remarkable results from the TAR-200 device, a groundbreaking intravesical drug-delivery system that eliminated visible cancer in approximately 82% of patients with high-risk non-muscle-invasive bladder cancer. These patients had previously failed standard BCG immunotherapy, leaving them with few alternatives beyond radical bladder removal surgery.

A new intravesical drug-delivery device, TAR-200, has demonstrated an 82% complete response rate in high-risk non-muscle-invasive bladder cancer patients who failed standard BCG therapy. The SunRISe-1 phase 2b study’s results, presented to medical authorities and highlighted by leading institutions, point toward a bladder-sparing option that could shift urological care in Thailand.

For Thai families facing bladder cancer, the path today often means radical cystectomy when non-muscle-invasive disease recurs or progresses. The traditional surgery removes the bladder and requires urinary reconstruction, a life-changing outcome that Thai patients weigh carefully against quality of life, dignity, and family responsibilities. TAR-200 offers a minimally invasive alternative that can be administered on an outpatient basis, potentially reducing hospital stays and preserving daily living.